NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET SEGMENTATION, PROFESSIONAL SURVEY RESEARCH
REPORT
The Global
Market is projected to grow
at
the
Non-lymphomas Hodgkin's are one of the most prevalent lymphomas, and thus one of the most common malignancies. It is potentially fatal if not treated adequately, and the patients diagnosed have a shortened life span. Market competitors are conducting clinical trials for the development of new non-Hodgkin lymphoma treatments, particularly for relapsed and refractory forms. Get a Sample PDF of the report -https:// www.extrapolate.com/sample/Healthcare-Medical-Devices- Biotechnolo gy/nonhodgkin-lymphoma-therapeutics-market/25718
Non-Hodgkin Lymphoma (NHL) Therapeutics
from USD 8.26 billion in 2021 to USD 12.14 billion by 2030
a CAGR of 8.4% during
forecast period.
Takeda Pharmaceutical Company Limited AstraZeneca Bayer AG Novartis AG Spectrum Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd. Bristol Myers Squibb Company Janssen Pharmaceuticals, Inc. Genentech, Inc. Merck & Co., Inc. Kyowa Kirin Co., Ltd. AbbVie Inc. Sanofi
LIST OF KEY COMPANIES PROFILED:
